Netherlands
· Delayed Price · Currency is EUR Vivoryon Therapeutics Statistics
Total Valuation
Vivoryon Therapeutics has a market cap or net worth of EUR 56.70 million. The enterprise value is 41.43 million.
| Market Cap | 56.70M |
| Enterprise Value | 41.43M |
Important Dates
The next estimated earnings date is Thursday, April 24, 2025.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vivoryon Therapeutics has 26.07 million shares outstanding. The number of shares has increased by 3.35% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 26.07M |
| Shares Change (YoY) | +3.35% |
| Shares Change (QoQ) | +6.30% |
| Owned by Insiders (%) | 11.57% |
| Owned by Institutions (%) | 19.70% |
| Float | 21.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 4.06 |
| P/TBV Ratio | 4.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.33 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.85 |
Financial Position
The company has a current ratio of 9.37, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.37 |
| Quick Ratio | 9.12 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -602.96 |
Financial Efficiency
Return on equity (ROE) is -112.35% and return on invested capital (ROIC) is -70.48%.
| Return on Equity (ROE) | -112.35% |
| Return on Assets (ROA) | -62.86% |
| Return on Capital (ROIC) | -70.48% |
| Revenue Per Employee | -241,333 |
| Profits Per Employee | -2.08M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.25% in the last 52 weeks. The beta is 1.88, so Vivoryon Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.88 |
| 52-Week Price Change | -73.25% |
| 50-Day Moving Average | 2.08 |
| 200-Day Moving Average | 1.87 |
| Relative Strength Index (RSI) | 57.56 |
| Average Volume (20 Days) | 301,111 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Vivoryon Therapeutics had revenue of EUR -3.62 million and -31.19 million in losses. Loss per share was -1.23.
| Revenue | -3.62M |
| Gross Profit | -3.10M |
| Operating Income | -31.35M |
| Pretax Income | -31.37M |
| Net Income | -31.19M |
| EBITDA | -31.27M |
| EBIT | -31.35M |
| Loss Per Share | -1.23 |
Balance Sheet
The company has 15.27 million in cash and 10,000 in debt, giving a net cash position of 15.26 million or 0.59 per share.
| Cash & Cash Equivalents | 15.27M |
| Total Debt | 10,000 |
| Net Cash | 15.26M |
| Net Cash Per Share | 0.59 |
| Equity (Book Value) | 13.98M |
| Book Value Per Share | 0.54 |
| Working Capital | 14.34M |
Cash Flow
In the last 12 months, operating cash flow was -14.56 million and capital expenditures -5,000, giving a free cash flow of -14.56 million.
| Operating Cash Flow | -14.56M |
| Capital Expenditures | -5,000 |
| Free Cash Flow | -14.56M |
| FCF Per Share | -0.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | 866.13% |
| Pretax Margin | 866.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vivoryon Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.35% |
| Shareholder Yield | -3.35% |
| Earnings Yield | -56.68% |
| FCF Yield | -25.69% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vivoryon Therapeutics has an Altman Z-Score of 18.09.
| Altman Z-Score | 18.09 |
| Piotroski F-Score | n/a |